The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 6, 2007, Pages 405-406

  Zdravkovic, M ^a   Kruse, M ^b   Rost, K L ^b   Moss J ^a   Kecskes, A ^b  

^a NOVO NORDISK A S   (Denmark)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

Clinical; Diabetes; NN414

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; PLACEBO; POTASSIUM CHANNEL ACTIVATING AGENT NN414; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTAL PARESTHESIA; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INSULIN RELEASE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL TUMOR; POTASSIUM TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WORKLOAD;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIC S-OXIDES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; TIME FACTORS;

EID: 34347220107     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-973062     Document Type: Article

References (4)

1. Leahy JL. Impaired β-cell function with chronic hyperglycemia: "overworked β-cell hypothesis". Diabetes Rev 1996; 4: 298-319
2. Carr RD, Brand CL, Bödvarsdottir TB, Hansen JB, Sturis J. NN414, a SUR1/ Kir6.2 selective potassium channel opener, reduces blood glucose and improves glucose tolerance in zucker obese rats. Diabetes 2003; 52: 2513-2518
3. Zdravkovic M, Kruse M, Rost KL, Moss J, Kecskes A, Dyrberg T. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener, in healthy male subjects. J Clin Pharmacol 2005; 45: 763-772
4. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Haeften T Van, Haring H, Fritsche A, Gerich J. Assessment of insulin secretion from the oral glucose tolerance test in white patients with type 2 diabetes. Diabetes Care 2000; 23: 1440-1441